Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.47−0.05 (-3.29%)
Close on Nov 13, 2026Market cap $84.46MP/E –Yield –
Black Diamond Therapeutics cash
Cash and short-term investments held at the end of each period.
Black Diamond Therapeutics's cash was $102.03M at Sep 30, 2026. For fiscal 2025 it was $128.65M, up 29.4% from the year before. The highest annual figure on record is $316.29M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.65M | +29.4% |
| FY2024 | Dec 31, 2024 | $99.39M | -24.8% |
| FY2023 | Dec 31, 2023 | $132.22M | +6.7% |
| FY2022 | Dec 31, 2022 | $123.98M | -41.2% |
| FY2021 | Dec 31, 2021 | $211.01M | -33.3% |
| FY2020 | Dec 31, 2020 | $316.29M | +104.4% |
| FY2019 | Dec 31, 2019 | $154.72M | +199.5% |
| FY2018 | Dec 31, 2018 | $51.66M | +555.8% |
| FY2017 | Dec 31, 2017 | $7.88M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $102.03M | -24.7% |
| Q2 FY2026 | Jun 30, 2026 | $110.51M | -22.6% |
| Q1 FY2026 | Mar 31, 2026 | $118.26M | -22.4% |
| Q4 FY2025 | Dec 31, 2025 | $128.65M | +29.4% |
| Q3 FY2025 | Sep 30, 2025 | $135.50M | +20.3% |
| Q2 FY2025 | Jun 30, 2025 | $142.83M | +16.1% |
| Q1 FY2025 | Mar 31, 2025 | $152.40M | +32.3% |
| Q4 FY2024 | Dec 31, 2024 | $99.39M | -24.8% |
| Q3 FY2024 | Sep 30, 2024 | $112.68M | -21.9% |
| Q2 FY2024 | Jun 30, 2024 | $122.97M | +37.4% |
| Q1 FY2024 | Mar 31, 2024 | $115.20M | +11.4% |
| Q4 FY2023 | Dec 31, 2023 | $132.22M | +6.7% |
| Q3 FY2023 | Sep 30, 2023 | $144.26M | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $89.53M | -44.4% |
| Q1 FY2023 | Mar 31, 2023 | $103.37M | -42.5% |
| Q4 FY2022 | Dec 31, 2022 | $123.98M | -41.2% |
| Q3 FY2022 | Sep 30, 2022 | $144.18M | -38.6% |
| Q2 FY2022 | Jun 30, 2022 | $160.89M | -38.9% |
| Q1 FY2022 | Mar 31, 2022 | $179.74M | -38.0% |
| Q4 FY2021 | Dec 31, 2021 | $211.01M | -33.3% |
| Q3 FY2021 | Sep 30, 2021 | $235.01M | -29.4% |
| Q2 FY2021 | Jun 30, 2021 | $263.47M | +28.8% |
| Q1 FY2021 | Mar 31, 2021 | $290.06M | -18.8% |
| Q4 FY2020 | Dec 31, 2020 | $316.29M | +104.4% |
| Q3 FY2020 | Sep 30, 2020 | $333.07M | +323.4% |
| Q2 FY2020 | Jun 30, 2020 | $204.49M | +415.7% |
| Q1 FY2020 | Mar 31, 2020 | $357.19M | +698.8% |
| Q4 FY2019 | Dec 31, 2019 | $154.72M | +199.5% |
| Q3 FY2019 | Sep 30, 2019 | $78.66M | +898.5% |
| Q2 FY2019 | Jun 30, 2019 | $39.65M | – |
| Q1 FY2019 | Mar 31, 2019 | $44.72M | – |
| Q4 FY2018 | Dec 31, 2018 | $51.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $7.88M | – |
See a number that looks wrong?